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the sucrose-fed rats. At the end of the experiment, the mean
weight of the kidneys of the sucrose-fed rats was 2.16 0.39 g,
and from starch-fed rats was 1.67 0.22 g (P<0.01). Focal
thickening of the glomerular basement membrane and fusion of the
foot processes of the epithelial cells was present in the sucrose-fed
rats. These animals also had characteristic concretions of calcium
in the corticomedullary region of the kidney. Determination of the
cation content of the kidneys demonstrated greatly elevated con-
centrations of calcium (8-fold), phosphorous (3-fold) and magne-
sium (1.5-fold). Thus, long-term feeding of a sucrose-rich diet
results in renal damage to the glomerulus and the renal tubules.
The mechanism by which sucrose induces renal damage is not
understood, and the relevance of these findings to the clinical
situations is being investigated.
Occurrence of dense intramembranous deposit membranoproli-
ferative glomerulonephritis (MPGN-DIMD), nephritic factor, and
partial lipodystrophy (PLO) in one of identical twins with recur-
rence after transplantation. R. B. Sterzel, W. Reichel°, P. Neu-
hans and F. Scheler. Medical Schools, Hannover and Gottingen,
Germany, and J. G. P. Sissons, Royal Postgraduate Medical
School, London, England. Sisters A and B are 22-yr-old monozy-
gous twins. A was healthy until aged 7 when she developed an
acute nephritic syndrome coinciding with an attack of varicella.
Following this, she developed the features of PLD, which became
more apparent over the next few years. She contracted various
viral and bacterial infections as an adolescent. Her glomerular
disease progressed slowly, and renal biopsies obtained at ages 17
and 18 showed MPGN with intramembranous electron dense
deposits; low serum C3 and the presence of nephritic factor were
repeatedly demonstrated. Hemodialysis was started at age 20.
Patient B is healthy with no signs of PLD. Her urinalysis and GFR
were normal as was a renal biopsy studied by light and immunoflu-
orescence microscopy; her serum complement profile was normal,
and nephritic factor was absent. At age 21, A received a renal
transplant from B. A also had bilateral nephrectomy; immuno-
suppression was prednisone, 25 mg/day, and azathiopnne, 100 mg/
day. Following transplantation, total hemolytic complement
remained low; for nine months GFR was greater than 80 mL'min,
but alter five months proteinuna (1 to 3 glday) recurred. A graft
biopsy at one month was normal on light microscopy, but immuno-
fluorescence revealed granular mesangial and capillary loop depo-
sition of C3. Biopsies at five and eight months after transplantation
showed more extensive staining for C3 and few small DIMD.
These observations in identical twins show that 1) nephritic factor
(and the associated complement activation), PLD, and dense
deposit MPGN do not have an exclusively genetic basis; 2) PLD
and MPGN may become apparent simultaneously, suggesting a
common cause—possibly varicella in twin A and, 3) posttran-
splant persistence of C3 activation and rapid glomerular deposition
of C3 (without detectable IgG and before demonstration of DIMD)
indicates a central role for altered C3 metabolism in the pathogen-
esis of MPGN-DIMD.
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Bone scintigraphy in renal osteodystrophy. P. de Graaf, I. M.
Schicht, E. K. J. Pauwels, andJ. de Graeff, University Hospital,
Leiden, The Netherlands. The value of bone scintigraphy in renal
osteodystrophy was studied in 30 patients on maintenance hemo-
dialysis, using Tc-99m EHDP. In order to reduce background
activity to levels found in normal controls, all patients were
dialyzed for five hours, starting 15 mm alter radionuclide adniinis-
tration. After six hours, qualitative and quantitative scintigraphic
skeletal examination took place. The results were compared with a
normal control group. All patients had histological proof of renal
osteodystrophy. Only 48% showed roentgenological abnormali-
ties. In contrast, 80% had pathological scintigrams. Increased
activity was noted mainly in the pelvis (46%), hips (60%), knees
(70%), ankles (53%), chest (42%), spine (42%), and skull (46%). In
addition, metastatic visceral calcifications were detected in some
patients. Quantitative analysis revealed increased skeletal activity
accumulation in all patients compared to controls, even when
scintigrams appeared normal. These findings suggest that bone
scintigraphy is superior to conventional roentgenological tech-
niques. Quantitative assessment of skeletal activity appears to be
an even more sensitive technique to detect renal osteodystrophy.
Do F(ab)2 alloantibodies induce immunologic enhancement? J.
L. J. Jansen, W. P. M. Tamboer, andR. A. P. Koene, Department
of Medicine, Division of Nephrology, Sint Radboudziekenhuis,
University of Njjmegen, The Netherlands. Alloantibodies directed
against transplantation antigens are not only capable of inducing
prolongation of graft survival (enhancement), but also of inducing
acute, complement-dependent, graft destruction. This latter
destructive activity makes the use of enhancing antisera in clinical
transplantation virtually impossible. The in vitro cytotoxic action
of antibodies is a function of the Fe fragment. The F(ab)2 frag-
ments of immunoglobulins are still capable of recognizing and
binding the corresponding antigens specifically, but they lack cyto-
toxic activity. If enhancement occurs as a result of "masking" of
transplantation antigens, it should be feasible to induce prolonga-
tion of graft survival by administration of F(ab)2 fragments without
the concurrent risk of acute destruction of the graft. This hypothe-
sis was tested in a skin graft model in the mouse (recipient B6AFI.
donor B 10.D2). In this model it is possible to induce enhancement
as well as acute, complement-dependent, destruction of skin grafts
by injection of the same B6AF1 anti-B 10.D2 serum. With F(ab)2
fragments prepared from this serum by digestion with pepsin, the
following results were obtained. 1) The F(ab)2 preparation was no
longer cytotoxic in vitro, but could block the cytotoxic activity of
undigested anti-B l0.D2 serum against BlO.D2 cells. This indicated
that the antigen-binding capacity was retained. 2) Alter digestion
of the antiserum, the destructive activity in vivo disappeared,
while, also in this case, .the preparation completely blocked the
destructive activity of normal antiserum that was administered
afterwards. 3) The F(ab)2 fragments, however, did not induce
prolongation of graft survival, not even if high doses were adminis-
tered. This suggests that masking of antigens alone is insufficient
to induce enhancement. Therefore, administration of specific
F(ab)3 antibodies in clinical transplantation to prevent rejection
does not seem to be a very fruitful approach.
High-dose bumetanide in patients with chronic renal insufficien-
cy and severe nephrotic syndrome. R. A. P. Koene. Department qf
Medicine, Division of Nephrology, Sint RadboudZiekenhuis, Uni-
versity of Nzjmegen, The Netherlands. Bumetanide is a new
diuretic that closely resembles furosemide and ethacrynic acid in
its mode of action. In patients with normal renal function, 1 mg
has a diuretic effect comparable to 40 mg of furosemide. Like
furosemide, it might be useful in the treatment of edema that is
resistant to conventional diuretics, such as chlorothiazide or chlor-
thalidone. We have, therefore, studied the effects of high-dose
bumetanide (15 to 50 mg) in five patients who had severe edema
' Dr. Reichel is deceased.
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due to nephrotic syndrome and/or renal failure. All patients were
admitted to the ward during the study and took a diet containing 10
to 20 mmoles of sodium/day. Bumetanide and furosemide were
given in a single dose in the morning. The dose-response curves
and the diuretic pattern were comparable with those of furosem-
ide. Three patients were treated with bumetanide and furosemide
in an alternating protocol. The potency ratio of bumetanide vs.
furosemide was found to be not 1/40, butwas closer to 1/20 Myalgia
was the only untoward side-effect noted. Bumetanide deserves a
place in the treatment of resistant edema, when so-called high-
ceiling diuretics are required.
Fructose intolerance as a type of proximal tubular acidosis in an
adult. M. Mussche, N. Lameire, S. Ringoir. University Hospital,
Ghent, Belgium. An adult patient with initially undiagnosed
hereditary fructose intolerance is described. The patient was
admitted with viral meningitis and fructose-containing solutions
were infused. A dramatic clinical picture of acute hepatic failure
with hemorrhagic syndrome, hypoglycemia with glucosuria, and a
severe proximal tubular acidosis developed (plasma bicarbonate,
16 mEq/liter; and bicarbonaturia, 236 mEq/24 hr). The hemorrhagic
disorder and the tubular acidosis disappeared within 24 hr after
recognition of the fructose intolerance and stopping the fructose
administration. The hepatic dysfunction lasted for three months.
After recovery, the activity of liver fructose- 1-phosphate-aldolase
was depressed (30% of normal). Subsequently, an i.v. fructose
tolerance test was performed: within 60 mm after initiation of the
fructose infusion, plasma bicarbonate dropped from 25 to 14 mEq/
liter and the urinary bicarbonate excretion rose from 10 to 111
jzEq/min. Plasma phosphate decreased from 4.4 to 2.6 mg/lOll ml,
concomitantly with an increase in renal phosphate clearance, from 9
to 20 mI/mm. Both plasma uric acid and urinary uric acid excretion
increased from 3.2 to 6.7 mgIlOO ml and from 0.39 to 21.0 mg/mm,
respectively. Blood lactate and pyruvate levels increased from 6.6
to 20.2 mg/l00 ml and from 0.9 to 1.98 mg/100 ml, respectively. Bio-
chemical evidence of hepatitic dysfunction was present, as bili-
rnbine, transaminases, and alkaline phosphatase were significantly
elevated above normal. All parameters normalized within three
hours after withdrawal of the fructose. Hypoglycemia during the
test was prevented by the simultaneous administration of glucose.
Although exceptional, this case illustrates that "routine" adminis-
tration of fructose-contalning solutions can provoke a dramatic
clinical situation in hereditary fructose intolerance. The occurrence
of a proximal tubular acidosis may alert the physician for the
existence of this disorder.
Influence of indomethacin therapy on the angiotensin H depen-
dency of blood pressure in Bartter's syndrome. G. Rasschaert, A.
Mast, W. Boels, S. Ringoir, N. Lameire. University Hospital,
Ghent, Belgium. Bartter's syndrome is characterized by a normo-
tensive state, although the renin-angiotensin system is very active.
Diminished responsiveness of the arteriolar wall to endogenous
angiotensin II (A11) and an increased production of renal prosta-
glandins are some of the possible explanations. The purpose of this
report was to examine the effect of a long term indomethacin
therapy (3 months) on the systemic blood pressure (BP) reactions
to exogenous A11 and to P113 (saralasin) infusions in a patient with
Bartter's syndrome. Blockade of the endogenous A11 by P113 before
and after indomethacin therapy has not been previously studied. A
50-yr-old male presented with a persistent hypokaliemia (2.4 mEq/
liter), metabolic alkalosis (bicarbonate, 36 mEq/liter), a high plas-
ma renin activity (PRA, 14 ng/ml/hr), and an elevated plasma
aldosterone (27 ng/lOO ml) with normal BP (110/80 mm Hg).
After exclusion of other causes of hypokaliemia, the diagnosis of
Bartter's syndrome was considered. Renal biopsy revealed hyper-
plasia of the juxtaglomernlar apparatus, while the plasma prosta-
glandin levels were elevated (1552 pg/ml PGF2a [normal is 400 pg/
ml]). A high pressor dose of 180 nglkg mm of exogenous A11 was
necessary to increase the diastolic BP with 25 mon of Hg. Infusion
of P113 in a dose of 2rg/kg min produced a sustained fall of 20 mm
of Hg in diastolic BP. Treatment with indomethacin, 2 mg/kg,
resulted in correction of the metabolic alkalosis and the normaliza-
tion of the plasma potassium concentration after ten days. Three
months following indomethacin therapy, a decrease to 7 ng/ml/hr
in PEA was noted, while the pressor dose of A11 was reduced to 77
ng/kg min. At this moment, a dose of 4 jsg/kg/min of P113 was
necessary to obtaln the same fall of 20 mm Hg in diastolic BP. The
hypotensive reaction after P113 infusion indicates that the arterioles
in a patient with Bartter's syndrome are still contractile to endoge-
nous A11 and that the elevated levels of endogenous A11 play an
important role in the malntenance of the normal blood pressure.
Although prolonged treatment with indomethacin reduces the
PRA, and presumably the levels of circulating endogenous A11, the
positive saralasin test reflects that they still contribute in the
malntenance of the normal blood pressure.
Experiences about the antihypertensive effect of prazosine. T.
Thien, R. A. P. Koene, J. G. M. C. Rosier, A. van 't Laor, P. G.
A. B. Wljdeveld. Department of Medicine, Sint Rodbondzieken-
huis, University ofN,jmegen. Prazosin (Minipress®), aquinazoline
derivate, is a recently marketed antihypertensive drug that is
supposed to act by arteriolar relaxation. The indications for its use
are renal and essential hypertension, and it is suggested that only
few side effects occur. We have studied the etlects of prazosin in
24 patients. Seventeen patients had renal hypertension, and seven
patients had essential hypertension. Nine patients received prazo-
sin alone. In the others the drug was added to their current
antihypertensive treatment, in most instances a combination of
propranolol and chlorthalidone. The means of three blood pressure
readings before prazosin administration were compared with three
values during a constant dose of prazosin. The mean prazosin dose
was 14 mg, and the mean follow up, 5 months. In the whole group,
the supine blood pressure dropped from 173/108 to 169/106mm Hg,
a mean arterial pressure (MAP) change of 2.3%. Standing blood
pressure decreased from 165/113 to 149/103mm Hg (9.2%). The best
effect was noted in the group in which prazosjn was added to /3-
blockade and diuretics, with a MAP decrease of 4.7% (supine) and
12.6% (standing). The following side effects were noted: collapse
after first dose (33%), orthostatic complaints (77%), nasal conges-
tion (33%), tiredness (42%), nausea and vomiting (38%), drowsi-
ness (25%), and headache (33%). Only three patients tolerated the
drug without complalnts. Our results suggest that prazosin has
only weak antihypertensive activity, which almost exclusively
becomes apparent in the upright position. This orthostatic hypo-
tension and also the other side effects better meet the criteria for
an a-sympathicolytic effect than for a direct vasodilatory action.
Recent experimental data in the literature support this conclusion.
Pathophysiology of the hypothalamic hypophyseal thyroid axis
in chronic hemodialysis patients. R. van Lensen, A. E. Meinders
and B. R. van Neerbos. Department of Internal Medicine, Munici-
pal Hospital, Arnhem. Previous results have shown the plasma T4
levels to be lower than normal and the plasma T3 levels to be in the
low normal range in about 50% of our hemodialysis patients.
Nevertheless an i.v. bolus injection of 200 og TRH (thyrotropin
releasing hormone) was followed by a clearly diminished increase
of plasma TSH (thyrotropin)-concentrations, compared to nor-
mals. Therefore two questions were ralsed: 1) Is continued TRH
stimulation followed by an adequate TSH-release and consequent
increase of plasma T4 and T3 levels? 2) Is the negative feedback
system intact, by which increased plasma T4 and T3 levels turn off
TSH release? Six hemodialysis patients received in between two
periods of hemodialysis 20 mg of TRH orally every 12 hr during
three days. Maximal plasma T4 and T3 levels were obtalned 24 to
48 hr (P < 0.005) following the initial dose. Plasma T3 levels rose
in five and plasma T4 levels in three out of the six patients to
thyrotoxic concentrations (for controls!). After 72 hr the plasma T4
and T3 concentrations were still significantly elevated compared to
the starting concentration (P < 0.005). Plasma TSH concentra-
tions reached peak values between 24 to 48 hr following the first
dose, and no significant difference was present between the plasma
concentrations measured at 0 and 72 hr. An i.v. bolus injec-
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tion of 200 g of TRII given at zero time did increase the
plasma TSH-concentration (after 20 mm) 2.0 to 5.3 i lU/mi. if
given at 72 hr, the rise was only 0.6 to 2.7 jz lU/mi. In a second
group of six patients, blood-samples were drawn at 0, 3, 6, 9, arid
12 hr after one 20-mg-capsule of TRH. The plasma TSH concen-
tration rose to maximum values between three and six hours; the
plasma T4 concentration started to increase at three hours, and the
plasma T3 concentration at six hours. Four out of the six patients
reacted with a slower and less pronounced increase of plasma
TSH, compared to normals. Conclusions: With repetitive exoge-
nous TRH administration, it is possible to increase TSH release
sufficiently enough to raise plasma T4 and T3 levels adequately.
The elevated plasma T4 and T3 levels evidently decrease TSH
release. The present and earlier results can best be explained by
assuming a low endogenous TRH release in chronic hemodialysis
patients.
Effect of interruption of a long-term therapy with indomethacin
in patients with chronic glomerulonephritis. Y. Vanrenterghem,
L. Roels and P. Michielsen. A.Z. St. Rafael, Leuven, Belgium. At
the start of a treatment with indomethacin in patients with glomer-
ulonephritis, a decrease in proteinuria usually occurs, together
with a decrease in GFR. This acute effect is more marked in the
presence of a nephrotic syndrome. In order to investigate the
extent to which the decrease in proteinuria observed during long
term treatment is linked to a decrease in GFR, the influence of an
interruption of the treatment has been evaluated in 95 patients with
chronic glomgrulonephritis, treated during at least six months. The
mean values of the creatinine clearance and proteinuria during the
last six months of therapy were compared with the mean values
during six months after interruption of indomethacin therapy.
Although in these 95 patients the mean value of the creatinine
clearance was unchanged, the proteinuria increased from 1.37 to
2.15 g/24 hr (P<0.001). The data were identical when only patients
who had been treated during more than two years were consid-
ered. According to the change in creatinine clearance after inter-
ruption of the treatment, the patients were then subdivided in three
subgroups: a group with a decrease of more than 5 mi/mm, an
unchanged group, and a group with an increase of more than 5 ml!
mm. In all, a significant increase in proteinuria was noted, respec-
tively + 0.74 g (P<O.001), + 1.11 g (0.0l<P<0.02) and 0.55 g
(0.01 <P<0.02). There was no significant difference between the
increases in proteinuria in the different subgroups. In 18 patients,
the proteinuria exceeded 3 g/24 hr. After interruption of the treat-
ment, the proteinuria increased from 4.44 g to 5.38 g/24 hr
(P<0.05), but the mean creatinine clearance remained unchanged
(57 to 52 ml/min [NS]). These results indicate that the decrease in
proteinuria obtained during a long term treatment with indometha-
cm is not due to a decrease in GFR.
